Eledon Pharmaceuticals (NASDAQ:ELDN) focuses on developing therapies aimed at addressing significant needs in transplantation and autoimmune diseases. Specializing in creating solutions that potentially reduce the need for life-long treatments, Eledon's projects revolve around leveraging scientific and technological advancements to better manage, and possibly cure, conditions that currently have limited treatment options. The company's objective is to pioneer breakthroughs that could transform patient care in its target areas, always pushing the limits of what's possible in the pharmaceutical sector to improve quality of life for those affected by these challenging diseases.